Clinical Trials Directory

Trials / Terminated

TerminatedNCT04854889

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia (LODACA): a Phase 2, Single-arm, Open-label Study

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
Sex
All
Age
12 Years
Healthy volunteers
Not accepted

Summary

This is a phase 2, single-center, single-arm, open-label trial. Simon's two-stage design is performed to evaluate the efficacy of low-dose Decitabine in refractory aplastic anemia.

Conditions

Interventions

TypeNameDescription
DRUGDecitabineDemethylating agents

Timeline

Start date
2021-04-22
Primary completion
2022-07-26
Completion
2022-08-09
First posted
2021-04-22
Last updated
2026-02-11

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04854889. Inclusion in this directory is not an endorsement.